Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has announced the completion of enrollment in its Phase 3 pivotal study, APPROACH, evaluating HLP003 for the adjunctive treatment of major depressive disorder (MDD). The company anticipates topline data in the fourth quarter of 2026, a milestone that could position HLP003 as a potential new therapeutic option for patients with inadequate response to standard antidepressants.
The APPROACH trial is part of the broader PARADIGM program, which also includes the EMBRACE study, currently enrolling participants, and the EXTEND long-term safety study, which is ongoing. These trials are designed to assess the efficacy and safety of HLP003, a proprietary NSA that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation underscores the potential of HLP003 to address a significant unmet need in MDD, particularly for patients who have not achieved adequate relief with existing therapies.
In addition to the HLP003 program, Helus Pharma is advancing HLP004 for generalized anxiety disorder (GAD). Following Phase 2 results that demonstrated a statistically significant and clinically meaningful improvement from baseline, the company expects to finalize the next study design by the end of the third quarter of 2026. HLP004 represents another potential treatment option in the company's pipeline, targeting a condition that affects millions worldwide.
The company also provided an update on its financial position, reporting cash and cash equivalents of $166.4 million as of June 30, 2026. This capital is expected to fund ongoing clinical development and operations. The quarterly net loss was $47.8 million, compared with $24.6 million in the same period last year, reflecting increased investment in the Phase 3 trials. Cash-based operating expenses rose to $37.5 million from $23.9 million a year earlier, driven by the advancement of the APPROACH, EMBRACE, and EXTEND studies.
Looking ahead, Helus Pharma is also progressing HLP005 toward candidate selection, with a viable development candidate anticipated in the second half of 2027. This early-stage program highlights the company's commitment to building a robust pipeline of novel serotonergic agonists aimed at addressing various mental health conditions.
The completion of enrollment in the APPROACH study is a critical step forward, as it brings the company closer to potentially delivering a new treatment for MDD. If the topline data are positive, HLP003 could offer a new mechanism of action that may provide durable improvements in depressive symptoms, addressing a significant public health concern. The company's focus on neuroplasticity and serotonin pathways represents an innovative approach in psychiatric medicine.
For more information on Helus Pharma and its pipeline, visit the company's newsroom at https://ibn.fm/HELP.
